Literature DB >> 12513963

The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined.

Richard S Swanson1, Carolyn C Compton, Andrew K Stewart, Kirby I Bland.   

Abstract

BACKGROUND: T3N0 colon cancer is the target of many adjuvant studies. Very few studies have examined the relationship of the number of lymph nodes examined to the prognosis of this stage. We examined data from the National Cancer Data Base (NCDB) to determine whether the number of examined lymph nodes is prognostic for T3N0 colon cancer.
METHODS: A total of 35,787 prospectively collected cases of T3N0 colon cancer that were surgically treated and pathologically reported from 1985 to 1991 to the NCDB as T3N0M0 were analyzed.
RESULTS: The 5-year relative survival rate for T3N0M0 colon cancer varied from 64% if 1 or 2 lymph nodes were examined to 86% if > 25 lymph nodes were examined. Three strata of lymph nodes (1-7, 8-12, and > or = 13) distinguished significantly different observed 5-year survival rates.
CONCLUSIONS: These results demonstrate that the prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. A minimum of 13 lymph nodes should be examined to label a T3 colon cancer as node negative. These data suggest that adjuvant trials for T3N0 colon cancer should stratify according to the number of lymph nodes examined.

Entities:  

Mesh:

Year:  2003        PMID: 12513963     DOI: 10.1245/aso.2003.03.058

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  169 in total

1.  Molecular staging estimates occult tumor burden in colorectal cancer.

Authors:  Alex Mejia; Stephanie Schulz; Terry Hyslop; David S Weinberg; Scott A Waldman
Journal:  Adv Clin Chem       Date:  2010       Impact factor: 5.394

2.  Lymph node harvest in colon and rectal cancer: Current considerations.

Authors:  James R McDonald; Andrew G Renehan; Sarah T O'Dwyer; Najib Y Haboubi
Journal:  World J Gastrointest Surg       Date:  2012-01-27

3.  Laparoscopic-assisted and open high anterior resection within an ERAS protocol.

Authors:  Ulf O Gustafsson; Marit Tiefenthal; Anders Thorell; Olle Ljungqvist; Jonas Nygrens
Journal:  World J Surg       Date:  2012-05       Impact factor: 3.352

4.  Colon cancer survival with herbal medicine and vitamins combined with standard therapy in a whole-systems approach: ten-year follow-up data analyzed with marginal structural models and propensity score methods.

Authors:  Michael McCulloch; Michael Broffman; Mark van der Laan; Alan Hubbard; Lawrence Kushi; Donald I Abrams; Jin Gao; John M Colford
Journal:  Integr Cancer Ther       Date:  2011-09-30       Impact factor: 3.279

5.  Ethnicity influences lymph node resection in colon cancer.

Authors:  Molly M Cone; Kelsea M Shoop; Jennifer D Rea; Kim C Lu; Daniel O Herzig
Journal:  J Gastrointest Surg       Date:  2010-08-17       Impact factor: 3.452

6.  Prognostic factors in node-negative colorectal cancer: a retrospective study from a prospective database.

Authors:  Gregoire Desolneux; Pascal Burtin; Emilie Lermite; Roberto Bergamaschi; Antoine Hamy; Jean Pierre Arnaud
Journal:  Int J Colorectal Dis       Date:  2010-04-20       Impact factor: 2.571

Review 7.  Adjuvant therapy for colon cancer.

Authors:  Olivia Aranha; Al B Benson
Journal:  Curr Gastroenterol Rep       Date:  2007-10

Review 8.  Colorectal cancer and lymph nodes: the obsession with the number 12.

Authors:  Giovanni Li Destri; Isidoro Di Carlo; Roberto Scilletta; Beniamino Scilletta; Stefano Puleo
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

9.  Is adjuvant chemotherapy beneficial to high risk stage II colon cancer? Analysis in a single institute.

Authors:  Chun-Chi Lin; Jen-Kou Lin; Shih-Ching Chang; Huann-Sheng Wang; Shung-Haur Yang; Jeng-Kai Jiang; Wei-Shone Chen; Tzu-Chen Lin
Journal:  Int J Colorectal Dis       Date:  2009-02-24       Impact factor: 2.571

Review 10.  Epidemiology and management options for colorectal cancer in children.

Authors:  Raya Saab; Wayne L Furman
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.